Email ID
Password
Scrip   
SkyePharma's Flutiform faces 12-month delay
02 September 2009
Asher Mullard

More clinical work is needed on SkyePharma's asthma drug, Flutiform (fluticasone propionate plus formoterol fumarate), says the US FDA, causing a potential 12-month delay to the drug's approval.

The drug, which is the company's lead candidate, was filed for the treatment of persistent asthma...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36